Document Detail

Premenopause contraception with monthly injectable Mesigyna with special emphasis on serum lipid and bone density patterns.
MedLine Citation:
PMID:  10906502     Owner:  NLM     Status:  MEDLINE    
This 2-year study compared Mesigyna(R) administered to 49 pre-menopausal women between 38 and 50 years, to 99 women fitted with an IUD (Nova-T). A complete lipoprotein assessment was carried out before treatment and at 6, 12, and 24 months of treatment. A bone densitometry was performed on half of the women, and an endometrial biopsy was taken from half of the Meisgyna group before and at the end of the first and second year. No pregnancy occurred with Mesigyna use while three pregnancies were observed with the IUD. The incidence of bleeding anomalies was higher in the Mesigyna group, with a discontinuation rate for these reasons of 20% versus 4% for IUD (p <0.05). The duration of bleeding days as well as dysmenorrhea were less with Mesigyna. No differences were seen in the pattern of intermenstrual bleeding and spinal bone density between both groups. No patient developed endometrial hyperplasia after treatment, thus endometrial risk seemed not to be increased. Total and LDL cholesterol, and apolipoproteins did not show modifications. A slight decrease in total triglycerides, HDL and HDL(2) cholesterol, and IDL lipoproteins was observed with Mesigyna. The present study appears to be the first using a monthly injectable hormonal contraceptive and monitoring its influence on lipid patterns in premenopausal women. Mesigyna proved to be a highly effective and low risk agent for premenopausal users.
E von Kesserü; J J Etchepareborda; R Wikinski; S Beier
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Contraception     Volume:  61     ISSN:  0010-7824     ISO Abbreviation:  Contraception     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-08-17     Completed Date:  2000-08-17     Revised Date:  2009-10-06    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  317-22     Citation Subset:  IM    
First Gynecological Clinic, University of Buenos Aires, Buenos Aires, Argentina.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Density*
Contraceptive Agents, Female / administration & dosage*,  adverse effects
Drug Combinations
Endometrium / pathology
Estradiol / analogs & derivatives*
Intrauterine Devices
Lipids / blood*
Middle Aged
Norethindrone / analogs & derivatives*
Patient Satisfaction
Uterine Hemorrhage / chemically induced
Reg. No./Substance:
0/Contraceptive Agents, Female; 0/Drug Combinations; 0/Lipids; 0/estradiol, norethindrone drug combination; 50-28-2/Estradiol; 68-22-4/Norethindrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mesigyna once-a-month combined injectable contraceptive: experience in Latin America.
Next Document:  Tubal ligation and risk of cervical cancer. The World Health Organiztion Collaborative Study of Neop...